Skip to main content

Table 1 Clinical characteristics of patients in both treatment groups

From: Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

Parameters Tofogliflozin group Conventional group P value
Sex (males) (%) 99 (58.6) 99 (58.2) 1.00
Age (years) 61.3 ± 9.3 60.9 ± 9.7 0.66
Current smoking 38 (22.6) 29 (17.1) 0.22
Hypertension 88 (52.1) 105 (61.8) 0.08
Dyslipidemia 107 (63.3) 122 (71.8) 0.11
Duration of diabetes (years) 12.1 ± 8.4 12.5 ± 8.3 0.65
Diabetic retinopathy 28 (16.8) 33 (19.5) 0.51
Diabetic nephropathy 48 (28.4) 53 (31.2) 0.58
Use of glucose-lowering agents 153 (90.5) 152 (89.4) 0.86
 Metformin 91 (53.8) 100 (58.8) 0.38
 Sulfonylurea 38 (22.5) 43 (25.3) 0.61
 Glinides 10 (5.9) 10 (5.9) 1.00
 Thiazolidinediones 18 (10.7) 23 (13.5) 0.51
 α-Glucosidase inhibitor 24 (14.2) 25 (14.7) 1.00
 DPP-4 inhibitors 75 (44.4) 95 (55.9) 0.039
 GLP-1 R agonists 23 (13.6) 12 (7.1) 0.05
 Insulins 35 (20.7) 37 (21.8) 0.89
Use of antihypertensive drugs 79 (46.7) 95 (55.9) 0.10
 Angiotensin-converting enzyme inhibitors 3 (1.8) 5 (2.9) 0.72
 Angiotensin II receptor blockers 63 (37.3) 83 (48.8) 0.037
 Direct renin inhibitor 2 (1.2) 0 (0.0) 0.25
 Calcium channel blocker 47 (27.8) 54 (31.8) 0.48
 Diuretic drugs 8 (4.7) 14 (8.2) 0.27
 α-Adrenergic receptor antagonist 2 (1.2) 0 (0.0) 0.25
 β-Adrenergic receptor antagonist 3 (1.8) 3 (1.8) 1.00
 Others 5 (3.0) 10 (5.9) 0.29
Use of lipid-lowering agents 82 (48.5) 99 (58.2) 0.08
 Statins 73 (43.2) 83 (48.8) 0.33
 Ezetimibe 10 (5.9) 11 (6.5) 1.00
 Resins 0 (0.0) 1 (0.6) 1.00
 Fibrates 8 (4.7) 6 (3.5) 0.60
Use of antithrombotic agents 17 (10.1) 15 (8.8) 0.71
 Antiplatelet agents 15 (8.9) 11 (6.5) 0.42
 Anticoagulants 2 (1.2) 4 (2.4) 0.68
 Others 0 (0.0) 0 (0.0)
  1. Data are presented as number (%) of patients or mean ± SD values